WO1997014806A3 - Delivery of biologically active polypeptides - Google Patents

Delivery of biologically active polypeptides Download PDF

Info

Publication number
WO1997014806A3
WO1997014806A3 PCT/GB1996/002580 GB9602580W WO9714806A3 WO 1997014806 A3 WO1997014806 A3 WO 1997014806A3 GB 9602580 W GB9602580 W GB 9602580W WO 9714806 A3 WO9714806 A3 WO 9714806A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
delivery
active polypeptides
delivery means
polypeptides
Prior art date
Application number
PCT/GB1996/002580
Other languages
French (fr)
Other versions
WO1997014806A2 (en
Inventor
Lothar Steidler
Erik Remaut
Jeremy Mark Wells
Page Richard William Falla Le
Original Assignee
Univ Cambridge Tech
Lothar Steidler
Erik Remaut
Jeremy Mark Wells
Page Richard William Falla Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT96935054T priority Critical patent/ATE435294T1/en
Priority to CA2234941A priority patent/CA2234941C/en
Application filed by Univ Cambridge Tech, Lothar Steidler, Erik Remaut, Jeremy Mark Wells, Page Richard William Falla Le filed Critical Univ Cambridge Tech
Priority to AU73154/96A priority patent/AU7315496A/en
Priority to BR9610929-7A priority patent/BR9610929A/en
Priority to NZ320418A priority patent/NZ320418A/en
Priority to KR1019980702803A priority patent/KR19990064308A/en
Priority to EP96935054A priority patent/EP0871748B1/en
Priority to DE69637961T priority patent/DE69637961D1/en
Priority to JP9515633A priority patent/JP2000508162A/en
Priority to DK96935054T priority patent/DK0871748T3/en
Publication of WO1997014806A2 publication Critical patent/WO1997014806A2/en
Publication of WO1997014806A3 publication Critical patent/WO1997014806A3/en
Priority to US09/060,878 priority patent/US6605286B2/en
Priority to NO19981746A priority patent/NO328224B1/en
Priority to AU24900/01A priority patent/AU774535B2/en
Priority to US10/350,250 priority patent/US20030202991A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Methods of delivering biologically active polypeptides and/or antigens, together with delivery means and pharmaceutical formulations comprising such delivery means.
PCT/GB1996/002580 1995-10-20 1996-10-21 Delivery of biologically active polypeptides WO1997014806A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP9515633A JP2000508162A (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides
DE69637961T DE69637961D1 (en) 1995-10-20 1996-10-21 ADMINISTRATION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
AU73154/96A AU7315496A (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides
CA2234941A CA2234941C (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides
NZ320418A NZ320418A (en) 1995-10-20 1996-10-21 Methods of delivering biologically active polypeptides and/or antigens with delivery means and pharmaceutical preparations
KR1019980702803A KR19990064308A (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides
DK96935054T DK0871748T3 (en) 1995-10-20 1996-10-21 Administration of biologically active polypeptides
AT96935054T ATE435294T1 (en) 1995-10-20 1996-10-21 ADMINISTRATION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
BR9610929-7A BR9610929A (en) 1995-10-20 1996-10-21 Processes for releasing one or more biologically active polypeptides, and one or more antigens, to regulate the functions of survival, growth, differentiation, effector or susceptibility to infection of cells or tissues, to reinforce an immune response against tumor cells or a colonized infection a distant or adjacent mucosal surface or tissue, to modulate the type of immune response (antibody versus cell-mediated) against a pathogenic infectious agent, to induce apoptosis in cells
EP96935054A EP0871748B1 (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides
US09/060,878 US6605286B2 (en) 1995-10-20 1998-04-16 Delivery of biologically active polypeptides
NO19981746A NO328224B1 (en) 1995-10-20 1998-04-17 Non-invasive, gram-positive bacteria and their use in the preparation of adjuvants or vaccines.
AU24900/01A AU774535B2 (en) 1995-10-20 2001-03-07 Delivery of biologically active polypeptides
US10/350,250 US20030202991A1 (en) 1995-10-20 2003-01-22 Delivery of biologically active polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521568.7A GB9521568D0 (en) 1995-10-20 1995-10-20 Delivery of biologically active polypeptides
GB9521568.7 1995-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/060,878 Continuation US6605286B2 (en) 1995-10-20 1998-04-16 Delivery of biologically active polypeptides

Publications (2)

Publication Number Publication Date
WO1997014806A2 WO1997014806A2 (en) 1997-04-24
WO1997014806A3 true WO1997014806A3 (en) 1997-08-21

Family

ID=10782670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002580 WO1997014806A2 (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides

Country Status (17)

Country Link
US (2) US6605286B2 (en)
EP (1) EP0871748B1 (en)
JP (2) JP2000508162A (en)
KR (1) KR19990064308A (en)
CN (1) CN1195860C (en)
AT (1) ATE435294T1 (en)
AU (1) AU7315496A (en)
BR (1) BR9610929A (en)
CA (1) CA2234941C (en)
DE (1) DE69637961D1 (en)
DK (1) DK0871748T3 (en)
ES (1) ES2328751T3 (en)
GB (1) GB9521568D0 (en)
NO (1) NO328224B1 (en)
NZ (1) NZ320418A (en)
WO (1) WO1997014806A2 (en)
ZA (1) ZA968806B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (en) * 1997-09-10 2006-04-26 维昂药品公司 Genetically modified tumor-targeted bacteria with reduced virulence
EP1123314B1 (en) * 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
FR2791998B1 (en) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech MODIFIED LACTOCOCCUS EXPRESSING CATALASE AND USES THEREOF
ATE342983T1 (en) 1999-07-05 2006-11-15 Vlaams Interuniv Inst Biotech PROVISION OF PEPTIDES WITH CLOVER LEAF STRUCTURE
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE60227498D1 (en) 2001-03-23 2008-08-21 Advanced Bionutrition Corp DISTRIBUTION OF AGENTS FOR THE CONTROL OF AFFECTS IN AQUACULTURE USING BIOACTIVE PROTEINS CONTAINING YEAST
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
EP1513545B1 (en) 2002-06-19 2008-03-19 Actogenix N.V. Methods and means to promote gut absorption
CA2489142C (en) * 2002-06-20 2013-11-26 Paul Francis Mckee Distributed computer
US20050129711A1 (en) * 2002-11-14 2005-06-16 Janakiraman Ramachandran Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
WO2004046346A2 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
GB0230331D0 (en) * 2002-12-31 2003-02-05 British Telecomm Method and apparatus for operating a computer network
CA2515298C (en) * 2003-02-06 2014-04-08 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
EP1592441B1 (en) * 2003-02-06 2012-04-11 Aduro Biotech Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP1599170B1 (en) * 2003-02-21 2013-01-16 Hasumi Llc (Dba Shukokai International) Human lymphocyte vaccine adjuvant
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
GB0412655D0 (en) * 2004-06-07 2004-07-07 British Telecomm Distributed storage network
US9200249B2 (en) 2004-08-20 2015-12-01 Actogenix N.V. Method to improve Lactococcus preservation
ATE511848T1 (en) 2004-08-25 2011-06-15 Us Gov Health & Human Serv LIVE MICROBIAL MICROBICIDES
KR20070057864A (en) 2004-08-26 2007-06-07 더 유니버시티 오브 웨스턴 온타리오 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
EP1871868A2 (en) 2005-04-15 2008-01-02 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
BRPI0615593A2 (en) * 2005-08-30 2011-05-24 Commw Scient And Ind Reseaech Organisation bacterial release of biologically active polypeptides
JP5049973B2 (en) * 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ Anti-TNFα producing lactic acid bacteria for the treatment of chronic enterocolitis
CA2631598C (en) 2005-11-29 2017-06-27 Actogenix Nv Induction of mucosal tolerance to antigens
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110182859A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
JP2009535380A (en) 2006-05-02 2009-10-01 アクトジェニックス・エヌブイ Microbial intestinal delivery of obesity-related peptides
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
US8759088B2 (en) 2007-01-12 2014-06-24 Actogenix N.V. Lactococcus promoters and uses thereof
JP2010516269A (en) 2007-01-25 2010-05-20 アクトジェニックス・エヌブイ Treatment of immune diseases by mucosal delivery of antigen
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
KR101821417B1 (en) 2009-04-30 2018-01-23 인트랙슨 액토바이오틱스 엔.브이. Cryoprotectants for freeze drying of lactic acid bacteria
EP2275527A1 (en) 2009-07-17 2011-01-19 ActoGeniX NV Animal component-free culture medium for bacterial fermentation
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
EP2343319A1 (en) 2010-01-07 2011-07-13 University of Ljubljana Genetically modified food grade microorganism for treatment of inflammatory bowel disease
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
JP2013530187A (en) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Compositions and methods for treating inflammatory diseases.
CN101921725B (en) * 2010-07-27 2013-06-05 浙江大学 Converter for inhibiting hen somatostatin action through oral immunization and application thereof
JP5991650B2 (en) * 2010-08-10 2016-09-14 国立研究開発法人農業・食品産業技術総合研究機構 Porcine erysipelas expressing cytokines and delivery method of cytokines using swine erysipelas
RU2644346C2 (en) 2011-06-01 2018-02-08 Интрексон Актобиотикс Н.В. System of polycistronic expression for bacteria
ES2676707T3 (en) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Modified gram positive bacteria and their uses
DK2758513T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
MX2015001751A (en) 2012-08-07 2015-11-13 Topgenix Inc Topical composition comprising transformed bacteria expressing a compound of interest.
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
JP6088648B2 (en) * 2013-06-11 2017-03-01 ハウスウェルネスフーズ株式会社 Carrier that delivers substances to phagocytic cells
US10064797B2 (en) 2014-06-17 2018-09-04 TopGeniX, Inc. Topical formulations for UV protection
EP3020816A1 (en) * 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
CN104476458B (en) * 2014-11-14 2016-08-17 中黔电气集团股份有限公司 A kind of low-voltage cabinet skeleton assembly or fitting table of band automatic clamping mechanism
AU2015370982B2 (en) 2014-12-23 2019-03-21 Ilya Pharma Ab Methods for wound healing
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3011331A1 (en) 2016-01-14 2017-07-20 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102015116B1 (en) * 2018-05-04 2019-10-21 (주)메디톡스 Extracellular vesicle isolated from recombinant microorganism comprising polynucleotide encoding target protein and use thereof
KR102553825B1 (en) * 2018-05-04 2023-07-13 (주)메디톡스 Extracellular vesicle isolated from recombinant microorganism comprising polynucleotide encoding target protein and use thereof
AU2019433065B2 (en) 2019-03-04 2022-08-18 Aurealis Therapeutics AG Chloride-inducible prokaryotic expression system

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176320A1 (en) * 1984-09-26 1986-04-02 Eli Lilly And Company A method for expression and secretion in bacillus
WO1990000594A2 (en) * 1988-07-07 1990-01-25 Whitehead Institute For Biomedical Research Recombinant mycobacterial expression vehicles and uses therefor
WO1991006654A1 (en) * 1989-11-01 1991-05-16 Cedars-Sinai Medical Center A method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
EP0449770A2 (en) * 1990-03-22 1991-10-02 Ciba-Geigy Ag Bacterial vectors
WO1993017117A1 (en) * 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
WO1995003418A2 (en) * 1993-07-22 1995-02-02 Beth Israel Hospital Association Recombinant bcg vaccines
WO1996011277A1 (en) * 1994-10-05 1996-04-18 Dompe' S.P.A. Microorganisms as therapeutic delivery systems

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
IL99097A0 (en) * 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
CA2099841C (en) * 1991-03-05 2003-02-25 Ian G. Charles Expression of recombinant proteins in attenuated bacteria
IL103530A0 (en) * 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
US5837509A (en) * 1992-12-30 1998-11-17 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
JP2000510332A (en) * 1996-04-19 2000-08-15 ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン Methods of stimulating an immune response by administering a host organism expressing intimin alone or as a fusion protein with one or more other antigens
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
ATE346931T1 (en) * 1997-06-20 2006-12-15 Intervet Int Bv CLOSTRIDIUM PERFRINGENS VACCINE
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
EP1123314B1 (en) * 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
ATE449861T1 (en) * 2000-10-20 2009-12-15 Bioneer As METHOD FOR THE FERMENTATIVE PRODUCTION OF HETEROLOGUE GENE PRODUCTS IN LACTIC ACID BACTERIA
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176320A1 (en) * 1984-09-26 1986-04-02 Eli Lilly And Company A method for expression and secretion in bacillus
WO1990000594A2 (en) * 1988-07-07 1990-01-25 Whitehead Institute For Biomedical Research Recombinant mycobacterial expression vehicles and uses therefor
WO1991006654A1 (en) * 1989-11-01 1991-05-16 Cedars-Sinai Medical Center A method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
EP0449770A2 (en) * 1990-03-22 1991-10-02 Ciba-Geigy Ag Bacterial vectors
WO1993017117A1 (en) * 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
WO1995003418A2 (en) * 1993-07-22 1995-02-02 Beth Israel Hospital Association Recombinant bcg vaccines
WO1996011277A1 (en) * 1994-10-05 1996-04-18 Dompe' S.P.A. Microorganisms as therapeutic delivery systems

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOERSMA ET AL: "LACTOBACILLUS AS VECTORS WITH INTRINSIC ADJUVANTICITY FOR SAFE LIVE MUCOSAL VACCINES", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 255, XP002027111 *
GASSON ET AL: "IN VIVO GENETIC SYSTEMS IN LACTIC ACID BACTERIA", FEMS MICROBIOLOGY REVIEWS, vol. 87, 1990, pages 43 - 60, XP000573739 *
NORTON ET AL: "PROGRESS IN THE DEVELOPMENT OF LACTOCOCCUS LACTIS AS A RECOMBINANT MUCOSAL VACCINE DELIVERY SYSTEM", FOLIA MICROBIOLOGICA, vol. 40, 1995, pages 225 - 230, XP000645430 *
STEIDLER ET AL: "SECRETION OF BIOLOGICALLY ACTIVE MURINE INTERLEUKIN-2 BY LACTOCOCCUS LACTIS SUBSP. LACTIS", APPLIED AND ENVIROMENTAL MICROBIOLOGY, vol. 61, no. 4, April 1995 (1995-04-01), pages 1627 - 1629, XP000616349 *

Also Published As

Publication number Publication date
GB9521568D0 (en) 1995-12-20
US20030202991A1 (en) 2003-10-30
CN1202934A (en) 1998-12-23
CA2234941C (en) 2010-09-21
WO1997014806A2 (en) 1997-04-24
JP2000508162A (en) 2000-07-04
NZ320418A (en) 2000-03-27
ES2328751T3 (en) 2009-11-17
MX9803093A (en) 1998-11-29
CA2234941A1 (en) 1997-04-24
BR9610929A (en) 1999-12-21
JP2008067708A (en) 2008-03-27
NO981746L (en) 1998-06-22
DK0871748T3 (en) 2009-10-19
DE69637961D1 (en) 2009-08-13
AU7315496A (en) 1997-05-07
NO981746D0 (en) 1998-04-17
US6605286B2 (en) 2003-08-12
KR19990064308A (en) 1999-07-26
CN1195860C (en) 2005-04-06
EP0871748A2 (en) 1998-10-21
ZA968806B (en) 1998-04-20
EP0871748B1 (en) 2009-07-01
US20010006642A1 (en) 2001-07-05
NO328224B1 (en) 2010-01-11
ATE435294T1 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO1997014806A3 (en) Delivery of biologically active polypeptides
ZA9710342B (en) Directional drug delivery stent and method of use.
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
AU9676198A (en) Drug delivery and gene therapy delivery system
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
ZA988203B (en) Aerosol medication delivery apparatus and system.
GEP20022707B (en) Biodegrading Macromers for the Controlled Release of Biologically Active Substances
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
AU1992595A (en) Hydrophobic drug delivery systems
ZA97831B (en) Sustained delivery of an active agent using an implantable system.
AU8935591A (en) Drug delivery system and method
AU8933391A (en) Medical drug formulation and delivery system
AU5954596A (en) Intravitreal microsphere drug delivery and method of prepara tion
AU3718797A (en) Nonocclusive drug delivery device and process for its manufacture
HK1016886A1 (en) Drug delivery system for two or more active substances
AU7796198A (en) Novel acoustically active drug delivery systems
AU1719800A (en) Drug delivery systems and methods
IL117706A0 (en) Powdered drug storage and delivery system
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
AU5783898A (en) Active delivery device and related procedures
WO1997037640A3 (en) Uniform drug delivery therapy
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
EP0960885A4 (en) Depsipeptides and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96198487.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2234941

Country of ref document: CA

Ref document number: 2234941

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09060878

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019980702803

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003093

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 320418

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996935054

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996935054

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980702803

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980702803

Country of ref document: KR